Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Padcev (enfortumab vedotin)
- ranolazine
Interactions between your drugs
ranolazine enfortumab vedotin
Applies to: ranolazine, Padcev (enfortumab vedotin)
Ranolazine may increase the blood levels of the active medication in enfortumab vedotin in some patients. This may increase the risk and/or severity of side effects such as nausea; vomiting; diarrhea; loss of appetite; tingling, numbness or burning in the hands and feet; muscle weakness; hyperglycemia (high blood sugar); skin reactions (rash, itching, hair loss); lung problems (trouble breathing, shortness of breath, cough); eye disorders (dry eyes, inflammation of the cornea, blurred vision); and low platelet and white blood cell counts. You may also be more likely to develop bleeding problems or infections due to low blood cell counts. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
ranolazine food
Applies to: ranolazine
You may take ranolazine with or without food, but should try to take it the same way every time. Grapefruit and grapefruit juice should be avoided if possible. Grapefruit juice can increase the levels of ranolazine in your body. High blood levels of food can occasionally cause an irregular heart rhythm that may be serious. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, or fast or pounding heartbeats during treatment with ranolazine. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Bavencio
Bavencio (avelumab) is a cancer medicine that interferes with the growth and spread of cancer cells ...
Balversa
Balversa (erdafitinib) is an oral kinase inhibitor that may be used to treat adults with locally ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Mutamycin
Mutamycin is used for bladder cancer, pancreatic cancer, stomach cancer
Erdafitinib
Erdafitinib is used for bladder cancer, urothelial carcinoma
Avelumab
Avelumab is used for merkel cell carcinoma, renal cell carcinoma, urothelial carcinoma
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.